Overview

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Status:
NOT_YET_RECRUITING

Trial end date:
2031-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.

Phase:

PHASE2

Details

Lead Sponsor:

Baptist Health South Florida

Collaborator:

Incyte Corporation

Treatments:

Radiotherapy
ruxolitinib
Temozolomide